By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to ...

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.

Investors who closely watch the healthcare sector are keeping an eye on Moderna (NASDAQ:MRNA) as its shares are up 12% over ...

Moderna stock jumped late Friday on reports the FDA's top vaccine official, Vinay Prasad, will step down amid mounting ...

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...